Search

Your search keyword '"Reni, M"' showing total 1,114 results
Start Over Author "Reni, M"
1,114 results on '"Reni, M"'

2. Survival analysis of the metastatic cohort of Italian Association of Medical Oncology (AIOM) GARIBALDI survey

Author

Reni, M., Giommoni, E., Bergamo, F., Cavanna, L., Simionato, F., Spada, M., Di Marco, M., Bernardini, I., Cordio, S.S., Latiano, T., Spallanzani, A., Silvestris, N., Cardellino, G.G., Bonomi, M., Milella, M., Luchena, G., Tamburini, E., Macchini, M., Orsi, G., Modesti, M., Procaccio, L., Santoni, A., De Simone, I., Caldirola, L., Galli, F., and Pinto, C.

Published
2024
Full Text
View/download PDF

3. Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey

Author

Reni, Michele, Macchini, Marina, Orsi, Giulia, Peretti, Umberto, Valente, Mariamaddalena, Giommoni, Elisa, Antonuzzo, Lorenzo, Di Costanzo, Francesco, Bergamo, Francesca, Zagonel, Vittorina, Lonardi, Sara, Buggin, Federica, Milella, Michele, Palmerio, Silvia, Cavanna, Luigi, Di Nunzio, Camilla, Di Marco, Maria Cristina, Grassi, Elisa, Spada, Massimiliano, Messina, Marco, Cordio, Stefano, Avola, Francesco, Aprile, Giuseppe, Pagano, Salvatore, Simionato, Francesca, Cardellino, Giovanni Gerardo, Majer, Federica, Maiello, Evaristo, Latiano, Tiziana Pia, Chiarazzo, Cinzia, Artioli, Fabrizio, Razzini, Giorgia, Pasqualini, Antonella, Ghidini, Michele, Binda, Elisa, Lazzarelli, Silvia, Bozzarelli, Silvia, Sala, Simona, Luppi, Gabriele, Pettorelli, Elisa, Spallanzani, Andrea, Vicario, Giovanni, Salmaso, Flavia, Basso, Marco, Silvestris, Nicola, Del Curatolo, Sabina, Zustovich, Fable, Bongiovanni, Francesca, Longobardi, Ciro, Sandi, Ilenia, Fontanella, Caterina, Montelatici, Silvia, Giordano, Monica, Luchena, Giovanna, Gilardoni, Micol, Tamburini, Emiliano, Rudnas, Britt, Venturini, Barbara, Merelli, Barbara, Negrini, Giorgia, Vici, Elio Maria, Marabese, Alessandra, Garetto, Cristina, Curcio, Paola, Cinieri, Saverio, Cinefra, Margherita, Ferrara, Pasqualinda, Cantore, Maurizio, Morselli, Patrizia, Fumi, Guglielmo, Isidori, Agnese, Ciccarese, Giovanni, Paolo Frassineti, Giovanni Luca, Pagan, Flavia, Vaccaro, Vanja, Spoto, Chiara, Ferrara, Marianna, Garufi, Carlo, Caporale, Marta, Vasile, Enrico, Salani, Francesca, Barone, Elisa, Berardi, Rossana, Onofri, Azzurra, Ballatore, Zelmira, Lucarelli, Alessandra, Barucca, Alessandra, Pancotti, Amedeo, Scipioni, Teresa, Bencardino, Katia, Marrapese, Giovanna, Idotta, Laura, Petrelli, Fausto, Lonati, Veronica, Ceribelli, Anna, Giuli, Angelo, Zannori, Cristina, Bassanelli, Maria, Mambrini, Andrea, Ginocchi, Laura, Orlandi, Massimo, Celio, Luigi, Niger, Monica, Biamonte, Lavinia, Tamberi, Stefano, Piancastelli, Alessandra, Papiani, Giorgio, Valli, Irene, Allione, Paolo, Boe, Maria Giovanna, Scartozzi, Mario, Lai, Eleonora, Pireddu, Annagrazia, Ziranu, Pina, Demurtas, Laura, Puzzoni, Marco, Mariani, Stefano, Pretta, Andrea, Liscia, Nicole, Savastano, Clementina, Malaspina, Valentina, Tonini, Giuseppe, Grassani, Teresa, Barco, Barbara, Pierosandro, Tagliaferri, Ciliberto, Domenico, Ierardi, Antonella, Calandruccio, Natale Daniele, Minotti, Vincenzo, Matocci, Roberta, Torri, Valter, Porcu, Luca, Rulli, Erica, De Simone, Irene, Carlucci, Luciano, Rulli, Eliana, Poli, Davide, Tonto, Paola, Scellato, Francesca, Pinto, Carmine, Reni, M., Giommoni, E., Bergamo, F., Milella, M., Cavanna, L., Di Marco, M.C., Spada, M., Cordio, S., Aprile, G., Cardellino, G.G., Maiello, E., Bernardini, I., Ghidini, M., Bozzarelli, S., Macchini, M., Orsi, G., De Simone, I., Rulli, Er., Porcu, L., Torri, V., and Pinto, C.

Published
2023
Full Text
View/download PDF

6. A basal-like pancreatic cancer molecular subtype can be identified on EUS-acquired tissue and is associated to current smoking, lower Ca19.9 expression and worse prognosis

Author

Archibugi, L., additional, Pisani, R. Ponz de Leon, additional, Lazzano, P., additional, Tacelli, M., additional, Zaccari, P., additional, Petrone, M. C., additional, Rossi, G., additional, Apadula, L., additional, Vanella, G., additional, Sette, C., additional, Doglioni, C., additional, Falconi, M., additional, Reni, M., additional, Arcidiacono, P., additional, and Capurso, G., additional

Published
2024
Full Text
View/download PDF

7. EUS-guided PORtal Vein Sampling for Isolation and characterization of Circulating tumour cells in pancreatic cancer patients (EUPhORIC): a pilot prospective study

Author

Vanella, G., additional, Felici, C., additional, Di Sario, G., additional, Lazarevic, D., additional, Rossella, V., additional, Morelli, M., additional, Apadula, L., additional, Tonon, G., additional, Doglioni, C., additional, Reni, M., additional, Falconi, M., additional, Capurso, G., additional, and Arcidiacono, P., additional

Published
2024
Full Text
View/download PDF

8. T.03.6: A BASAL-LIKE PANCREATIC CANCER MOLECULAR SUBTYPE CAN BE IDENTIFIED ON EUS-ACQUIRED TISSUE AND IS ASSOCIATED TO SMOKING, LOWER CA19.9 ANDWORSE PROGNOSIS

Author

Archibugi, L., primary, De Leon Pisani, R. Ponz, additional, Lazzano, P., additional, Tacelli, M., additional, Zaccari, P., additional, Petrone, M.C., additional, Rossi, G., additional, Vanella, G., additional, Apadula, L., additional, Sette, C., additional, Doglioni, C., additional, Reni, M., additional, Falconi, M., additional, Arcidiacono, P.G., additional, and Capurso, G., additional

Published
2024
Full Text
View/download PDF

9. OC.12.6: EUS-GUIDED PORTAL VEIN SAMPLING FOR ISOLATION AND CHARACTERIZATION OF CIRCULATING TUMOUR CELLS IN PANCREATIC CANCER PATIENTS (EUPHORIC): A PILOT PROSPECTIVE STUDY

Author

Vanella, G., primary, Felici, C., additional, Di Sario, G., additional, Lazarevic, D., additional, Rossella, V., additional, Maurizio, A., additional, Apadula, L., additional, Bucci, G., additional, Tonon, G., additional, Doglioni, C., additional, Reni, M., additional, Falconi, M., additional, Capurso, G., additional, and Arcidiacono, P.G., additional

Published
2024
Full Text
View/download PDF

11. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey

Author

Orsi, G., Di Marco, M., Cavaliere, A., Niger, M., Bozzarelli, S., Giordano, G., Noventa, S., Rapposelli, I.G., Garajova, I., Tortora, G., Rodriquenz, M.G., Bittoni, A., Penzo, E., De Lorenzo, S., Peretti, U., Paratore, C., Bernardini, I., Mosconi, S., Spallanzani, A., Macchini, M., Tamburini, E., Bencardino, K., Giommoni, E., Scartozzi, M., Forti, L., Valente, M.M., Militello, A.M., Cascinu, S., Milella, M., and Reni, M.

Published
2021
Full Text
View/download PDF

13. Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort

Author

Peretti, U., Cavaliere, A., Niger, M., Tortora, G., Di Marco, M.C., Rodriquenz, M.G., Centonze, F., Rapposelli, I.G., Giordano, G., De Vita, F., Stuppia, L., Avallone, A., Ratti, M., Paratore, C., Forti, L.G., Orsi, G., Valente, M.M., Gaule, M., Macchini, M., Carrera, P., Calzavara, S., Simbolo, M., Melisi, D., De Braud, F., Salvatore, L., De Lorenzo, S., Chiarazzo, C., Falconi, M., Cascinu, S., Milella, M., and Reni, M.

Published
2021
Full Text
View/download PDF

16. Bone metastases in biliary cancers: A multicenter retrospective survey

Author

Santini, D, Brandi, G, Aprile, G, Russano, M, Cereda, S, Leone, F, Lonardi, S, Fornaro, L, Scartozzi, M, Silvestris, N, Barni, S, Pantano, F, Vincenzi, B, Palloni, A, Frega, G, Casagrande, M, Ferrari, L, Dadduzio, V, Intini, R, Filippi, R, Vasile, E, Vivaldi, C, Faloppi, L, Brunetti, O, Reni, M, Aglietta, M, and Tonini, G

Published
2018
Full Text
View/download PDF

18. Feasibility of the biopsychosocial primary care intervention 'Back on Track' for patients with chronic low back pain

Author

Ivan P.J. Huijnen, Albère Köke, Jeanine A. Verbunt, Reni M. A. van Erp, Rob J. E. M. Smeets, Revalidatiegeneeskunde, and RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation

Subjects
Biopsychosocial model, medicine.medical_specialty, Process (engineering), medicine.medical_treatment, treatment fidelity, QUESTIONNAIRE, Physical Therapy, Sports Therapy and Rehabilitation, EXPECTANCY, Primary care, FEAR, COST-EFFECTIVENESS, 03 medical and health sciences, 0302 clinical medicine, CREDIBILITY, Intervention (counseling), GRADED ACTIVITY, Medicine, In patient, 030212 general & internal medicine, ATTITUDES, EXPOSURE IN-VIVO, Rehabilitation, business.industry, DISABILITY, cognitive behavioural therapy, humanities, process evaluation, physiotherapists, Chronic low back pain, primary health care, Physical therapy, CLINICAL MANAGEMENT, Process evaluation, business, human activities, 030217 neurology & neurosurgery
Abstract

Purpose: Literature shows promising effects for interdisciplinary biopsychosocial rehabilitation programs in patients with chronic low back pain (CLBP). Not every patient needs an interdisciplinary rehabilitation trajectory provided in a secondary care setting. Patients with moderate complex psychosocial complaints might benefit from biopsychosocial interventions offered in primary care under supervision of a physician in rehabilitation medicine (i.e. biopsychosocial integrated care intervention). This study investigated the feasibility and effectiveness of such intervention in patients with CLBP with moderate complex psychosocial complaints.Methods: mixed-method. Patients (aged 18-65 years, low back pain >= 12 weeks, moderate complex psychosocial complaints) received the intervention (4 individual sessions, 8 group sessions) provided by trained primary care physiotherapists. Physicians in rehabilitation medicine provided one consultation afterwards. Data from patients (n = 18), physicians (n = 4) and physiotherapists (n = 12) were used.Results: Physiotherapists were satisfied with the training. Patient attendance was good for individual sessions, less for groups. Physiotherapists sufficiently delivered the intervention, although recruitment and contextual factors influenced delivery. Patients reported significantly reduced functional disability (Quebec Back Pain Disability Scale) post-treatment (-8.3, 95% CI -13.3 to -2.7) and at 3 months follow-up (-7.6, 95% CI -12.9 to -2.2).Conclusions: A biopsychosocial integrated intervention is feasible and potentially effective in patients with CLBP.

Published
2022
Full Text
View/download PDF

20. Alternation of MRI and EUS in pancreatic cancer screening could increase detection of both pancreatic and extra-pancreatic findings

Author

Archibugi, L., additional, Pisani, R. Ponz de Leon, additional, Coluccio, C., additional, Zaccari, P., additional, Binda, C., additional, Petrone, M. C., additional, Rossi, G., additional, Falconi, M., additional, Reni, M., additional, Arcidiacono, P. G., additional, Carlo, F., additional, and Capurso, G., additional

Published
2023
Full Text
View/download PDF

21. Regret affects the choice between neoadjuvant therapy and upfront surgery for potentially resectable pancreatic cancer

Author

Cucchetti, A., Djulbegovic, B., Crippa, S., Hozo, I., Sbrancia, M., Tsalatsanis, A., Binda, C., Fabbri, C., Salvia, R., Falconi, M., Ercolani, G., Alfieri, Sergio, Amato, A., Amisano, M., Anderloni, A., Maestri, A., Coluccio, C., Brandi, G., Casadei-Gardini, A., Cennamo, V., Crino, S. F., Valle, R. D., De Angelis, C., Di Battista, M., Di Maio, M., Di Marco, M., Di Matteo, F., Di Mitri, R., Ettorre, G. M., Facciorusso, A., Farina, G., Ferrari, G., Fornaro, L., Frigerio, I., Frisone, D., Fuccio, L., Gardini, A., Garufi, C., Giampieri, R., Grazi, G. L., Jovine, E., Kauffmann, E., Langella, S., Larghi, Alberto Leonardo, Manno, M., Marciano, E., Marzioni, M., Merighi, A., Mutignani, M., Nardo, B., Niger, M., Palmisano, V., Partelli, S., Pinto, C., Piras, E., Rapposelli, I. G., Reni, M., Ricci, C., Rimassa, L., Siena, S., Spada, Cristiano, Sperti, E., Spezzaferro, M., Sposito, C., Tamberi, S., Troisi, R., Veneroni, L., Vivarelli, M., Zerbi, A., Alfieri S. (ORCID:0000-0002-0404-724X), Larghi A., Spada C. (ORCID:0000-0002-5692-0960), Cucchetti, A., Djulbegovic, B., Crippa, S., Hozo, I., Sbrancia, M., Tsalatsanis, A., Binda, C., Fabbri, C., Salvia, R., Falconi, M., Ercolani, G., Alfieri, Sergio, Amato, A., Amisano, M., Anderloni, A., Maestri, A., Coluccio, C., Brandi, G., Casadei-Gardini, A., Cennamo, V., Crino, S. F., Valle, R. D., De Angelis, C., Di Battista, M., Di Maio, M., Di Marco, M., Di Matteo, F., Di Mitri, R., Ettorre, G. M., Facciorusso, A., Farina, G., Ferrari, G., Fornaro, L., Frigerio, I., Frisone, D., Fuccio, L., Gardini, A., Garufi, C., Giampieri, R., Grazi, G. L., Jovine, E., Kauffmann, E., Langella, S., Larghi, Alberto Leonardo, Manno, M., Marciano, E., Marzioni, M., Merighi, A., Mutignani, M., Nardo, B., Niger, M., Palmisano, V., Partelli, S., Pinto, C., Piras, E., Rapposelli, I. G., Reni, M., Ricci, C., Rimassa, L., Siena, S., Spada, Cristiano, Sperti, E., Spezzaferro, M., Sposito, C., Tamberi, S., Troisi, R., Veneroni, L., Vivarelli, M., Zerbi, A., Alfieri S. (ORCID:0000-0002-0404-724X), Larghi A., and Spada C. (ORCID:0000-0002-5692-0960)

Abstract

Background: When treating potentially resectable pancreatic adenocarcinoma, therapeutic decisions are left to the sensibility of treating clinicians who, faced with a decision that post hoc can be proven wrong, may feel a sense of regret that they want to avoid. A regret-based decision model was applied to evaluate attitudes to-ward neoadjuvant therapy versus upfront surgery for potentially resectable pancreatic adenocarcinoma.Methods: Three clinical scenarios describing high-, intermediate-, and low-risk disease-specific mortality after upfront surgery were presented to 60 respondents (20 oncologists, 20 gastroenterologists, and 20 surgeons). Respondents were asked to report their regret of omission and commission regarding neo-adjuvant chemotherapy on a scale between 0 (no regret) and 100 (maximum regret). The threshold model and a multilevel mixed regression were applied to analyze respondents' attitudes toward neo-adjuvant therapy.Results: The lowest regret of omission was elicited in the low-risk scenario, and the highest regret in the high-risk scenario (P < .001). The regret of the commission was diametrically opposite to the regret of omission (P < .001). The disease-specific threshold mortality at which upfront surgery is favored over the neoadjuvant therapy progressively decreased from the low-risk to the high-risk scenarios (P <=.001). The nonsurgeons working in or with lower surgical volume centers (P = .010) and surgeons (P = .018) accepted higher disease-specific mortality after upfront surgery, which resulted in the lower likelihood of adopting neoadjuvant therapy.Conclusion: Regret drives decision making in the management of pancreatic adenocarcinoma. Being a surgeon or a specialist working in surgical centers with lower patient volumes reduces the likelihood of recommending neoadjuvant therapy.(c) 2023 Elsevier Inc. All rights reserved.

Published
2023

22. CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

Author

Chiorean, E.G., Von Hoff, D.D., Reni, M., Arena, F.P., Infante, J.R., Bathini, V.G., Wood, T.E., Mainwaring, P.N., Muldoon, R.T., Clingan, P.R., Kunzmann, V., Ramanathan, R.K., Tabernero, J., Goldstein, D., McGovern, D., Lu, B., and Ko, A.

Published
2016
Full Text
View/download PDF

25. OC.09.5 ALTERNATION OF MRI AND EUS IN PANCREATIC CANCER SCREENING COULD INCREASE DETECTION OF BOTH PANCREATIC AND EXTRA-PANCREATIC FINDINGS

Author

Ponz De Leon Pisani, R., primary, Archibugi, L., additional, Coluccio, C., additional, Zaccari, P., additional, Binda, C., additional, Petrone, M.C., additional, Rossi, G., additional, Falconi, M., additional, Reni, M., additional, Arcidiacono, P., additional, Fabbri, C., additional, and Capurso, G., additional

Published
2023
Full Text
View/download PDF

28. Peningkatan Kompetensi Manajemen Asfiksia Bayi Baru Lahir Melalui Metode Cooperative-Learning

Author

Reni M. Kusuma, Anita D. Anwar, and Dwi Prasetyo

Subjects
cooperative learning, competence, teacher-centered learning, Education, Medicine
Abstract

Background: The competence of asphyxia management on newborn baby is essential for midwife. The quality of learning process should be improved by applying interactive learning method. The cooperative learning method is often applied to enhance the effectiveness of clinical learning process. The purpose of this research was to analyze the influence of cooperative learning on competence which consists of student’s knowledge, attitude, and skill in comparison to teacher-centered learning method. Method: This is quasi-experimental research with control group pre-test and post-test design Samples were third semester students at Stikes A. Yani Yogyakarta. The samples were 80 students in cooperative learning group and 90 students in teacher-centered learning group. Result: The result showed that there was an improvement of knowledge in cooperative learning group compared to teacher-centered learning group (p=0.002). The improvement od student’s attitude in cooperative learning group was significantly higher than teacher-centered learning group (p=0.001). In the field of skills, cooperative group, although not significant (p=0.671). The competence was significantly higher in cooperative learning group rather than in teacher-centered learning group (p=0.027). Correlation between competence and method of learning was weak (rpbi = 0.134, p= 0.041). Conclusion: Cooperative learning method is proven to be improve student’s knowledge, attitude and skills. The difference is not significant for skills domain. Cooperative learning method is proven to improve student’s competence in carrying out the management of newborn babies asphyxia, even though the correlation is weak.

Published
2014
Full Text
View/download PDF

29. Epidemiology and geographic distribution of BRCA1-2 and DNA Damage response genes pathogenic variants in pancreatic ductal adenocarcinoma patients

Author

Macchini M., Centonze F., Peretti U., Orsi G., Militello A. M., Valente M. M., Cascinu S., Reni M., Macchini, M., Centonze, F., Peretti, U., Orsi, G., Militello, A. M., Valente, M. M., Cascinu, S., and Reni, M.

Subjects
BRCA2 Protein, Epidemiology, BRCA1 Protein, Pharmaco-ethnicity, General Medicine, Prognosis, BRCA1-2 pathogenic variants, Pancreatic Neoplasms, Oncology, Familiar pancreatic cancer, DNA Damage Response pathogenic variants, Humans, Radiology, Nuclear Medicine and imaging, Pancreatic adenocarcinoma, Germ-Line Mutation, Carcinoma, Pancreatic Ductal, DNA Damage
Abstract

Incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing over the last years, while patients prognosis remains grim. Recently germline BRCA1 and 2 pathogenic variants (gBRCA1-2) have emerged as risk factors for PDAC development, as well as new predictors of response to specific therapeutic interventions. However, data on gBRCA1-2 incidence in PDAC are currently sparse and limited to selected categories of patients, as for positive cancer history cases, for patients affected only by early or late stages of disease and mainly from the North-American population, thus generating incomplete information about the gBRCA1/2 epidemiology. In Western Countries gBRCA1-2 incidence ranges between 4.5% and 8% in unselected PDAC patients, raising up to 26% in cohorts with positive family cancer history. To date a limited number of studies from Asian countries are available, reporting a 10% as highest incidence of gBRCA1-2 in familiar PDAC, claiming at least in part a role of ethnicity in the gBRCA1-2 incidence and in other genes potentially implicated in the therapeutic decisions. Drawing a better defined map for the incidence of gBRCA1-2 and other germline pathogenic variants of DNA Damage Response genes (gDDR) might help assessing the therapeutic strategies for mutated patients according to the geographic areas. These informations may enhance the chance to predict efficacy and toxicity of selected chemotherapy regimens, fostering the development and implementation of the pharmaco-ethnicity knowledge in the routine-clinical practice, and increasing the awareness of the potential incorrect generalization of trials results outside of the geographic area where they are conducted.

Published
2021

30. 1298P Extended overall survival results from the POLO study of active maintenance olaparib in patients with metastatic pancreatic cancer and a germline BRCA mutation

Author

Hammel, P., primary, Golan, T., additional, Reni, M., additional, Van Cutsem, E., additional, Macarulla Mercade, T., additional, Hall, M., additional, Park, J.O., additional, Hochhauser, D., additional, Arnold, D., additional, Oh, D-Y., additional, Reinacher-Schick, A., additional, Tortora, G., additional, Algül, H., additional, O'Reilly, E., additional, Sharan, K., additional, Ou, X., additional, Cui, K.Y., additional, Locker, G., additional, and Kindler, H., additional

Published
2022
Full Text
View/download PDF

31. 1307P Real-world impact of olaparib use in advanced pancreatic cancer (PC) patients (pts) harboring germline BRCA1/2 (gBRCA) mutations

Author

Milella, M., primary, Orsi, G., additional, Palloni, A., additional, Salvatore, L., additional, Procaccio, L., additional, Noventa, S., additional, Bozzarelli, S., additional, Garajova, I., additional, Vasile, E., additional, Giordano, G., additional, Macchini, M., additional, Cavaliere, A., additional, Gaule, M., additional, Lonardi, S., additional, Di Marco, M.C., additional, Tortora, G., additional, Sperduti, I., additional, and Reni, M., additional

Published
2022
Full Text
View/download PDF

33. 1534TiP Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients-VESPA trial

Author

Budillon, A., Silvestro, L., Reni, M., Milella, M., Tortora, G., Rodriguez, M., Fiore, F., Petrillo, A., De Bellis, M., Cavalcanti, E., Macchini, M., Leone, A., Di Gennaro, E., Passaro, E., Borrelli, M., García Bermejo, M.L., Hewitt, E., Fuchs, C., Giannarelli, D., and Avallone, A.

Published
2024
Full Text
View/download PDF

37. Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial

Author

Golan T, Kindler HL, Park JO, Reni M, Macarulla T, Hammel P, Van Cutsem E, Arnold D, Hochhauser D, McGuinness D, Locker GY, Goranova T, Schatz P, Liu YZ, Hall MJ., Golan, T, Kindler, Hl, Park, Jo, Reni, M, Macarulla, T, Hammel, P, Van Cutsem, E, Arnold, D, Hochhauser, D, Mcguinness, D, Locker, Gy, Goranova, T, Schatz, P, Liu, Yz, and Hall, Mj.

Published
2020

39. Training and validation of a robust PET radiomic-based index predicting distant-relapse-free-survival after radiochemotherapy of patients with locally advanced pancreatic cancer

Author

Mori, M., primary, Passoni, P., additional, Incerti, E., additional, Broggi, S., additional, Reni, M., additional, Whybra, P., additional, Spezi, E., additional, Slim, N., additional, Vanoli, E.G., additional, Bettinardi, V., additional, Gianolli, L., additional, Picchio, M., additional, Di Muzio, N.G., additional, and Fiorino, C., additional

Published
2021
Full Text
View/download PDF

40. Effectiveness of Primary Care Interventions Using a Biopsychosocial Approach in Chronic Low Back Pain

Author

Jos Kleijnen, Reni M. A. van Erp, Ivan P.J. Huijnen, Rob J. E. M. Smeets, and Marluuke Jakobs

Subjects
Biopsychosocial model, Adult, medicine.medical_specialty, CLINICAL IMPORTANCE, GROUP TRAINING PROTOCOL, Psychological intervention, Review Article, FEAR, urologic and male genital diseases, Acceptance and commitment therapy, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, systematic review, 030202 anesthesiology, law, GRADED ACTIVITY, medicine, Humans, Pain Management, biopsychosocial intervention, low back pain, COMMITMENT THERAPY, OUTCOMES, business.industry, Chronic pain, ACCEPTANCE, medicine.disease, Low back pain, primary health care, Anesthesiology and Pain Medicine, Systematic review, TRIALS, GUIDELINE, Physical therapy, medicine.symptom, business, chronic pain, PHYSIOTHERAPY, Psychosocial, 030217 neurology & neurosurgery, hormones, hormone substitutes, and hormone antagonists
Abstract

Background and Objective Recent systematic reviews show promising effects for multidisciplinary biopsychosocial (BPS) interventions in patients with chronic low back pain (CLBP). Nowadays, BPS interventions have also been developed for primary care physiotherapy settings. Our aim was to systematically review the evidence on the effectiveness of primary care BPS interventions in improving functional disability, pain, and work status for patients with CLBP. Secondly, we aimed to provide an elaborated overview of BPS intervention designs, physiotherapist training programs, and process‐related factors (practical implementation). Methods We searched in scientific databases and reference lists. Randomized controlled trials (RCTs) evaluating primary care physiotherapist‐led BPS interventions in adults (≥18 years) with nonspecific CLBP (≥12 weeks) were included. Results Our search resulted in 943 references; 7 RCTs were included (1,426 participants). Results show moderate‐quality evidence (3 trials; 991 participants) that a BPS intervention is more effective than education/advice for reducing disability and pain in the short, medium, and long term. Low‐quality evidence (4 trials; 435 participants) was found for no difference with physical activity treatments. Conclusions BPS interventions seem more effective than education/advice and were found to be as effective as physical activity interventions in patients with CLBP. BPS interventions with a clear focus on psychosocial factors (understanding pain, unhelpful thoughts, coping styles, and goal setting) seem most promising. Sufficient delivery of BPS elements is expected when physiotherapists participate in training programs with extensive support prior and during delivery (manual, supervision, and informative resources).

Published
2019
Full Text
View/download PDF

41. 1466P Napabucasin + nab-paclitaxel with gemcitabine in patients (pts) with metastatic pancreatic adenocarcinoma (mPDAC): Results from the phase III CanStem111P study

Author

Bekaii-Saab, T., primary, Okusaka, T., additional, Goldstein, D., additional, Oh, D-Y., additional, Ueno, M., additional, Ioka, T., additional, Fang, W., additional, Anderson, E.C., additional, Noel, M.S., additional, Reni, M., additional, Choi, H.J., additional, Goldberg, J., additional, Oh, S.C., additional, Li, C-P., additional, Tabernero, J., additional, Li, J., additional, Foos, E., additional, Oh, C., additional, and Van Cutsem, E., additional

Published
2021
Full Text
View/download PDF

42. OC.03.7 ENDOSCOPIC ULTRASOUND-GUIDED ABLATION WITH HYBRIDTHERM PROBE IN ADDITION TO CHEMOTHERAPY VERSUS CHEMOTHERAPY ALONE FOR THE TREATMENT OF LOCALLY ADVANCED OR BORDERLINE RESECTABLE PANCREATIC CANCER: A PHASE II RANDOMIZED CONTROLLED TRIAL

Author

Testoni, S.G.G., primary, Petrone, M.C., additional, Reni, M., additional, Rossi, G., additional, Barbera, M., additional, Nicoletti, V., additional, Gusmini, S., additional, Balzano, G., additional, Linzenbold, W., additional, Enderle, M., additional, Della–Torre, E., additional, De Cobelli, F., additional, Doglioni, C., additional, Falconi, M., additional, Capurso, G., additional, and Arcidiacono, P.G., additional

Published
2021
Full Text
View/download PDF

43. 1467P POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer

Author

Arnold, D., primary, Golan, T., additional, Hammel, P., additional, Reni, M., additional, Van Cutsem, E., additional, Macarulla Mercade, T., additional, Hall, M.J., additional, Park, J.O., additional, Hochhauser, D., additional, Oh, D-Y., additional, Reinacher-Schick, A., additional, Tortora, G., additional, Algül, H., additional, O'Reilly, E.M., additional, Bordia, S., additional, McGuinness, D., additional, Cui, K.Y., additional, Locker, G., additional, and Kindler, H., additional

Published
2021
Full Text
View/download PDF

44. 1479P Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv)

Author

Orsi, G., primary, Milella, M., additional, Nappo, F., additional, Di Marco, M., additional, Niger, M., additional, Bozzarelli, S., additional, Rodriquenz, M.G., additional, Noventa, S., additional, Giordano, G., additional, Rapposelli, I.G., additional, Bernardini, I., additional, Vasile, E., additional, Macchini, M., additional, Peretti, U., additional, Valente, M.M., additional, Paratore, C., additional, Spallanzani, A., additional, Scartozzi, M., additional, Cascinu, S., additional, and Reni, M., additional

Published
2021
Full Text
View/download PDF

45. 1468P POLO: Subsequent therapy after maintenance olaparib in patients with a germline BRCA mutation and metastatic pancreatic cancer

Author

Golan, T., primary, Hammel, P., additional, Reni, M., additional, Van Cutsem, E., additional, Macarulla Mercade, T., additional, Hall, M.J., additional, Park, J.O., additional, Hochhauser, D., additional, Arnold, D., additional, Oh, D-Y., additional, Reinacher-Schick, A., additional, Tortora, G., additional, Algül, H., additional, O'Reilly, E.M., additional, Bordia, S., additional, McGuinness, D., additional, Cui, K.Y., additional, Locker, G., additional, and Kindler, H., additional

Published
2021
Full Text
View/download PDF

46. AF.104 RNA-SEQUENCING OF PANCREATIC CANCER FROM EUSACQUIRED TISSUE IS USEFUL TO DEFINE MOLECULAR SUBTYPES AND PROGNOSIS

Author

Archibugi, L., primary, Ruta, V., additional, Panzeri, V., additional, Redegalli, M., additional, Testoni, S.G.G., additional, Petrone, M.C., additional, Zaccari, P., additional, Tacelli, M., additional, Falconi, M., additional, Reni, M., additional, Doglioni, C., additional, Sette, C., additional, Arcidiacono, P.G., additional, and Capurso, G., additional

Published
2021
Full Text
View/download PDF

47. PO-1225 Hypofractionated radiotherapy after induction chemotherapy for advanced pancreatic cancer

Author

Passoni, P., primary, Broggi, S., additional, Slim, N., additional, Longobardi, B., additional, Mori, M., additional, Peretti, U., additional, Macchini, M., additional, Orsi, G., additional, Balzano, G., additional, Castoldi, R., additional, Falconi, M., additional, Del Vecchio, A., additional, Cattaneo, G.M., additional, Fiorino, C., additional, Cascinu, S., additional, Reni, M., additional, and Di Muzio, N.G., additional

Published
2021
Full Text
View/download PDF

49. LBA-1 Phase 3 APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) vs gemcitabine (Gem) alone in patients with resected pancreatic cancer (PC): Updated 5-year overall survival

Author

Tempero, M., primary, O'Reilly, E., additional, Van Cutsem, E., additional, Berlin, J., additional, Philip, P., additional, Goldstein, D., additional, Tabernero, J., additional, Borad, M., additional, Bachet, J., additional, Parner, V., additional, Tebbutt, N., additional, Chua, Y., additional, Corrie, P., additional, Harris, M., additional, Taieb, J., additional, Burge, M., additional, Kunzmann, V., additional, Zhang, G., additional, McGovern, D., additional, Marks, H., additional, Biankin, A., additional, and Reni, M., additional

Published
2021
Full Text
View/download PDF

50. SO-3 Treatment sequences and prognostic factors in metastatic pancreatic ductal adenocarcinoma: Univariate and multivariate analyses of a real-world study in Europe

Author

Taieb, J., primary, Hammel, P., additional, Reni, M., additional, Palmer, D., additional, Bridgewater, J., additional, Cubillo, A., additional, Prager, G., additional, Bayle, S., additional, Hédouin-Biville, F., additional, Teng, Z., additional, Seufferlein, T., additional, and Macarulla, T., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results